Exercise can improve sleep quality: a systematic review and meta-analysis

Background Insomnia is common. However, no systematic reviews have examined the effect of exercise on patients with primary and secondary insomnia, defined as both sleep disruption and daytime impairment. This systematic review and meta-analysis aimed to examine the effectiveness/efficacy of exercise in patients with insomnia. Methods We searched the Cochrane Central Register of Controlled Trials, MEDLINE, Embase, PsycINFO, World Health Organization International Clinical Trials Registry Platform, and ClinicalTrials.gov to identify all randomized controlled trials that examined the effects of exercise on various sleep parameters in patients with insomnia. All participants were diagnosed with insomnia, using standard diagnostic criteria or predetermined criteria and standard measures. Data on outcome measures were subjected to meta-analyses using random-effects models. The Cochrane Risk of Bias Tool and Grading of Recommendations, Assessment, Development, and Evaluation approach were used to assess the quality of the individual studies and the body of evidence, respectively. Results We included nine studies with a total of 557 participants. According to the Pittsburgh Sleep Quality Index (mean difference [MD], 2.87 points lower in the intervention group; 95% confidence interval [CI], 3.95 points lower to 1.79 points lower; low-quality evidence) and the Insomnia Severity Index (MD, 3.22 points lower in the intervention group; 95% CI, 5.36 points lower to 1.07 points lower; very low-quality evidence), exercise was beneficial. However, exercise interventions were not associated with improved sleep efficiency (MD, 0.56% lower in the intervention group; 95% CI, 3.42% lower to 2.31% higher; moderate-quality evidence). Only four studies noted adverse effects. Most studies had a high or unclear risk of selection bias. Discussion Our findings suggest that exercise can improve sleep quality without notable adverse effects. Most trials had a high risk of selection bias. Higher quality research is needed

Retrospective multicenter registry for endovascular treatment with newer devices in over 25‐cm femoropopliteal artery disease: A retrospective observational study

Abstract Background and Aims Endovascular therapy (EVT) is recommended in femoropopliteal (FP) lesions shorter than 25 cm by current guidelines; however, diffuse FP lesions remains challenging for EVT. The aim of this study was to investigate the efficacy of EVT with the latest devices for FP lesions longer than 25 cm. Methods This retrospective multicenter registry analyzed patients presented peripheral artery disease (PAD) having FP lesions longer than 25 cm who underwent EVT using the latest devices between 2017 and 2021. The primary outcome was restenosis 1 year after EVT. Results The present study enrolled a total of 504 PAD patients with 614 lesions undergoing EVT for diffuse FP lesions. The Kaplan–Meier analysis showed that the rates of freedom from restenosis and clinically‐driven target lesion revascularization were 79.3% and 82.4% 1 year after EVT, respectively. The multivariate Cox proportional hazards regression analysis showed that clinical features associated independently with restenosis risk were cilostazol use (adjusted hazard ratio, 0.49 [0.32–0.74]; p = 0.001), reference vessel diameter (RVD) (0.72 [0.58–0.89] per 1‐mm increase; p = 0.002), and P3 segment involvement (2.08 [1.33–3.26]; p = 0.001). The Kaplan–Meier analysis was conducted to compare the primary patency between cases with and without a small RVD, P3 involvement, and/or lack of cilostazol; any risk factors were related to a worse primary patency rate, compared with cases without risk factors. Conclusion In the current EVT era, the primary patency at 1 year was acceptable at 79.3% in patients with FP lesions longer than 25 cm. A small vessel and P3 segment involvement might be associated with a poor 1‐year patency rate after EVT, whereas cilostazol administration might contribute to reducing restenosis

sj-tiff-3-jet-10.1177_15266028221124727 – Supplemental material for Retrospective Multicenter Comparison Between Viabahn Covered Stent-Grafts and Supera Interwoven Nitinol Stents for Endovascular Treatment in Severely Calcified Femoropopliteal Artery Disease: The ARMADILLO Study (Adjusted Retrospective coMparison of scAffolDs In caLcified LesiOns)

Supplemental material, sj-tiff-3-jet-10.1177_15266028221124727 for Retrospective Multicenter Comparison Between Viabahn Covered Stent-Grafts and Supera Interwoven Nitinol Stents for Endovascular Treatment in Severely Calcified Femoropopliteal Artery Disease: The ARMADILLO Study (Adjusted Retrospective coMparison of scAffolDs In caLcified LesiOns) by Kazunori Horie, Mitsuyoshi Takahara, Tatsuya Nakama, Akiko Tanaka, Kazuki Tobita, Naoki Hayakawa, Shinsuke Mori, Yo Iwata and Kenji Suzuki in Journal of Endovascular Therapy</p

sj-tiff-2-jet-10.1177_15266028221124727 – Supplemental material for Retrospective Multicenter Comparison Between Viabahn Covered Stent-Grafts and Supera Interwoven Nitinol Stents for Endovascular Treatment in Severely Calcified Femoropopliteal Artery Disease: The ARMADILLO Study (Adjusted Retrospective coMparison of scAffolDs In caLcified LesiOns)

Supplemental material, sj-tiff-2-jet-10.1177_15266028221124727 for Retrospective Multicenter Comparison Between Viabahn Covered Stent-Grafts and Supera Interwoven Nitinol Stents for Endovascular Treatment in Severely Calcified Femoropopliteal Artery Disease: The ARMADILLO Study (Adjusted Retrospective coMparison of scAffolDs In caLcified LesiOns) by Kazunori Horie, Mitsuyoshi Takahara, Tatsuya Nakama, Akiko Tanaka, Kazuki Tobita, Naoki Hayakawa, Shinsuke Mori, Yo Iwata and Kenji Suzuki in Journal of Endovascular Therapy</p

sj-docx-1-jet-10.1177_15266028221124727 – Supplemental material for Retrospective Multicenter Comparison Between Viabahn Covered Stent-Grafts and Supera Interwoven Nitinol Stents for Endovascular Treatment in Severely Calcified Femoropopliteal Artery Disease: The ARMADILLO Study (Adjusted Retrospective coMparison of scAffolDs In caLcified LesiOns)

Supplemental material, sj-docx-1-jet-10.1177_15266028221124727 for Retrospective Multicenter Comparison Between Viabahn Covered Stent-Grafts and Supera Interwoven Nitinol Stents for Endovascular Treatment in Severely Calcified Femoropopliteal Artery Disease: The ARMADILLO Study (Adjusted Retrospective coMparison of scAffolDs In caLcified LesiOns) by Kazunori Horie, Mitsuyoshi Takahara, Tatsuya Nakama, Akiko Tanaka, Kazuki Tobita, Naoki Hayakawa, Shinsuke Mori, Yo Iwata and Kenji Suzuki in Journal of Endovascular Therapy</p

sj-docx-1-jet-10.1177_15266028241231472 – Supplemental material for Multicenter Registry of Common Femoral Artery Disease Treated With Endovascular Revascularization Using Interwoven Nitinol Stents: An Observational Retrospective Study

Supplemental material, sj-docx-1-jet-10.1177_15266028241231472 for Multicenter Registry of Common Femoral Artery Disease Treated With Endovascular Revascularization Using Interwoven Nitinol Stents: An Observational Retrospective Study by Kazunori Horie, Mitsuyoshi Takahara, Tatsuya Nakama, Kazuki Tobita, Akiko Tanaka, Yoshiaki Shintani, Yoshinori Tsubakimoto, Naoki Yoshioka, Naoki Hayakawa, Shinya Sasaki, Yo Iwata, Kenji Ogata, Tomonari Takagi, Tatsuki Doijiri and Masahiko Fujihara in Journal of Endovascular Therapy</p